InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (32 ops.)
Browse the full record of transactions filed by HO WILLIAM, Chief Medical Officer. Officer active across 1 companies, notably RAPT Therapeutics, Inc.. In total, 44 disclosures have been published. Total volume traded: €1.5m. The latest transaction was disclosed on 11 April 2022 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations44 total
€10,149920 shares@ €11.03150.6% of flow
Common Stock
SEC:0001593968-22-000857:0·
€63,2033,000 shares@ €21.06763.9% of flow
Common Stock
SEC:0001593968-22-000845:0·
€3,989695 shares@ €5.73990.2% of flow
Common Stock
SEC:0001593968-22-000827:0·
€50,4163,000 shares@ €16.80523.1% of flow
Common Stock
SEC:0001593968-22-000574:0·
€1,910347 shares@ €5.50560.3% of flow
Common Stock
SEC:0001593968-22-000424·
€1,910347 shares@ €5.50560.1% of flow
Common Stock
SEC:0001593968-22-000424:0·
€80,4173,000 shares@ €26.805610.8% of flow
Common Stock
SEC:0001593968-22-000215·
€80,4173,000 shares@ €26.80565.0% of flow
Common Stock
SEC:0001593968-22-000215:0·
€9,4981,737 shares@ €5.46791.3% of flow
Common Stock
SEC:0001593968-22-000168·
€9,4981,737 shares@ €5.46790.6% of flow
Common Stock
SEC:0001593968-22-000168:0·
€85,5993,000 shares@ €28.53311.5% of flow
Common Stock
SEC:0001593968-21-002528·
€85,5993,000 shares@ €28.5335.3% of flow
Common Stock
SEC:0001593968-21-002528:0·
€76,7873,000 shares@ €25.595710.3% of flow
Common Stock
SEC:0001593968-21-002273·
€76,7873,000 shares@ €25.59574.7% of flow
Common Stock
SEC:0001593968-21-002273:0·
€68,2002,000 shares@ €34.109.1% of flow
Common Stock
SEC:0001593968-21-002159·
€68,2002,000 shares@ €34.104.2% of flow
Common Stock
SEC:0001593968-21-002159:0·
€20,342616 shares@ €33.02322.7% of flow
Common Stock
SEC:0001593968-21-002152·
€20,342616 shares@ €33.02321.3% of flow
Common Stock
SEC:0001593968-21-002152:0·
€91,4793,000 shares@ €30.49312.3% of flow
Common Stock
SEC:0001593968-21-002105·
€91,4793,000 shares@ €30.4935.7% of flow
Common Stock
SEC:0001593968-21-002105:0·
€27,2241,000 shares@ €27.22423.7% of flow
Common Stock
SEC:0001593968-21-001985·
€27,2241,000 shares@ €27.22421.7% of flow
Common Stock
SEC:0001593968-21-001985:0·
€37,4123,690 shares@ €10.13885.0% of flow
Common Stock
SEC:0001593968-21-001948·
€37,4123,690 shares@ €10.13882.3% of flow
Common Stock
SEC:0001593968-21-001948:0·
€1,812347 shares@ €5.22070.2% of flow
Common Stock
SEC:0001593968-21-001941·
25 of 44 declarations
About HO WILLIAM
William Ho, M.D., Ph.D., is Chief Medical Officer of RAPT Therapeutics, a U.S.-listed biopharmaceutical company focused on immunology and inflammatory disease. He has served in this role since May 2015, making him one of the company’s long-tenured medical leaders. At RAPT, his responsibilities have centered on guiding clinical strategy, supporting the progression of pipeline assets through early development, and helping translate scientific programs into clinical data and future development milestones. Within the company’s evolving portfolio, he has been associated with the clinical development of programs in oncology and inflammatory disease, an area that requires strong expertise in both regulatory execution and translational medicine. Before joining RAPT, Ho served as Vice President of Clinical Development at Igenica Biotherapeutics, where he led the clinical development of antibody-based therapeutics. Prior to that, he spent seven years at Genentech in the Exploratory Clinical Development (BioOncology) group, where he led the clinical development of multiple small-molecule, antibody, and antibody-drug conjugate programs across a range of stages from IND filing through Phase 3. One of the most notable highlights of that period was his involvement in the clinical development of Gazyva (obinutuzumab). His career reflects deep experience at the intersection of oncology, immunology, and translational drug development. Ho earned an A.B. in Molecular Biology from Princeton University and holds both an M.D. and a Ph.D. in Microbiology and Immunology from Stanford University School of Medicine. He completed additional medical training at the University of California, San Francisco, and later at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy and contributed to early work relevant to CAR-T technology. This combination of academic training, clinical exposure, and industry leadership positions him as a seasoned biotech executive in the U.S. life sciences sector.
